Floatz logo

Rivastigmine

Cognitive Disorder

VA Office of Research and DevelopmentSmall moleculePhase 4 / ApprovedDormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
81/ 100

Competitive context

150 Active assets in the Cognitive Disorder cohort.

Asset / SponsorPhaseRating
Nicotine
University of Southern California
Phase 2BBB
Oxybutynin
University of Alberta
Phase 4BBB
LEVODOPA
Vanderbilt University Medical Center
Phase 4BB
Metformin
Fudan University
Phase 4BB
Seroquel®
Emory University
Phase 4BB

View all 50 →

Same molecule, other indications

Rivastigmine is also rated in:

Alzheimer diseaseDormant
BBB
Indicative ·
73 / 100
View asset →
cognitive disorderDormant
BBB
Indicative ·
73 / 100
View asset →
Parkinson diseaseDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →